Buy or sell Nerium Biotechnology stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

View More Companies

Nerium Biotechnology Stock

Nerium Biotechnology engages in the development of oleander-based products for the treatment of proliferative diseases and viral infections.

About Nerium Biotechnology Stock

Nerium Biotechnology, Inc., a biotechnology company, engages in the development of oleander-based products for the treatment of certain forms of proliferative diseases and viral infections. Its lead product includes Anvirzel, which is used to treat various forms of cancer. The company’s product line also comprises HIviral for the treatment of HIV/AIDS; HEP-viral for the treatment of hepatitis C; and NeriumAD, a skin cream for age-defying treatment. Nerium Biotechnology, Inc. is based in San Antonio, the United States.

Funding History

March 2011$289K

Management

Director

John F. O'Donnell

CEO & Chairman of the Board of Directors

Dennis Ray Knocke

CFO

Joseph B. Nester

Other Companies

American Gene Technologies International Logo
Learn More
Learn More
American Gene Technologies International
American Gene Technologies develops bio-safe lentivirus therapies to treat cancer, HIV/AIDS, and other chronic human disorders.
15Age (years)
$1.7MTotal Funding
Arsenal Medical Logo
Learn More
Learn More
Arsenal Medical
Arsenal Medical develops novel products that improve local therapy for injuries and diseases.
17Age (years)
$52.2MTotal Funding
Chesson Laboratory Associates Logo
Learn More
Learn More
Chesson Laboratory Associates
Chesson Laboratory Associates is a healthcare products company developing polymer-based medical care products in the United States.
16Age (years)
$2.0MTotal Funding
Gliknik Logo
Learn More
Learn More
Gliknik
Gliknik develops therapies for patients with cancer and immune disorders.
15Age (years)
$53.6MTotal Funding
PrognomiQ Logo
Learn More
Learn More
PrognomiQ
PrognomiQ is a biotechnology firm that develops test products to detect early disease detection through the power of multi-omics data.
2Age (years)
$101MTotal Funding

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 280K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo